Magnetic nanoparticle hyperthermia cancer treatment efficacy dependence on cellular and tissue level particle concentration and particle heating properties

Author(s):  
Alicia A. Petryk ◽  
Adwiteeya Misra ◽  
Courtney M. Mazur ◽  
James D. Petryk ◽  
P. J. Hoopes
Author(s):  
Kassianne J Tofani ◽  
Saeed Tiari

Abstract Magnetic nanoparticle hyperthermia (MNH) is a localized cancer treatment which uses an alternating magnetic field to excite magnetic nanoparticles (MNPs) injected into a tumor, causing them to generate heat. Once the temperature of the tumor tissue reaches about 43°C, the cancerous cells die. Different types of MNPs have been studied, including iron oxides with various coatings, Cu-Ni alloys and complex manganese/zinc particles. This paper reviews different types of MNPs and assesses them by magnetization, SAR, and Curie Temperature. We reviewed the achievements and limitations of the works in this field. A major issue with MNH is maintaining effective hyperthermia while preserving healthy tissue. Numerical modeling can predict temperature distribution and safely simulate hyperthermia. The most used bioheat transfer equation is Pennes' equation which includes a term for blood perfusion, an important factor for temperature distribution. While some models safely neglect it, most include blood perfusion term. Some recent models have also included large blood vessels, others used their own heat transfer models. This article reviews the different models and classifies them based on how they address blood flow. A need for studies with realistic tumor shapes was identified. The irregular shape of most tumors could result in less uniform temperature distribution than in the commonly used circular or spherical models. This article aims to identify potential future work to create more realistic tumor models.


2013 ◽  
Vol 29 (8) ◽  
pp. 845-851 ◽  
Author(s):  
Alicia A. Petryk ◽  
Andrew J. Giustini ◽  
Rachel E. Gottesman ◽  
Peter A. Kaufman ◽  
P. Jack Hoopes

2017 ◽  
Vol 139 (5) ◽  
Author(s):  
Alexander LeBrun ◽  
Tejashree Joglekar ◽  
Charles Bieberich ◽  
Ronghui Ma ◽  
Liang Zhu

The objective is to validate a designed heating protocol in a previous study based on treatment efficacy of magnetic nanoparticle hyperthermia in prostate tumors. In vivo experiments have been performed to induce temperature elevations in implanted PC3 tumors injected with magnetic nanoparticles, following the same heating protocol designed in our previous microCT-based theoretical simulation. A tumor shrinkage study and histological analyses of tumor cell death are conducted after the heating. Tumor shrinkage is observed over a long period of 8 weeks. Histological analyses of the tumors after heating are used to evaluate whether irreversible thermal damage occurs in the entire tumor region. It has been shown that the designed 25 min heating (Arrhenius integral Ω ≥ 4 in the entire tumor) on tumor tissue is effective to cause irreversible thermal damage to PC3 tumors, while reducing the heating time to 12 min (Ω ≥ 1 in the entire tumor) results in an initial shrinkage, however, later tumor recurrence. The treated tumors with 25 min of heating disappear after only a few days. On the other hand, the tumors in the control group without heating show approximately an increase of more than 700% in volume over the 8-week observation period. In the undertreated group with 12 min of heating, its growth rate is smaller than that in the control group. In addition, results of the histological analysis suggest vast regions of apoptotic and necrotic cells, consistent with the regions of significant temperature elevations. In conclusion, this study demonstrates the importance of imaging-based design for individualized treatment planning. The success of the designed heating protocol for completely damaging PC3 tumors validates the theoretical models used in planning heating treatment in magnetic nanoparticle hyperthermia.


Author(s):  
Gerwin Heller

SummaryImmunotherapy is one of the major breakthroughs in cancer treatment. However, many patients do not benefit from this type of therapy. Thus, there is an urgent need for a strategy to predict treatment efficacy before start of therapy. The role of certain genetic and epigenetic factors as potential predictive markers for response to immunotherapy is discussed in this short review.


Sign in / Sign up

Export Citation Format

Share Document